You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Development of a protein drug for pancreatic cancer treatment
SBC: ProDa BioTech L.L.C. Topic: NCIAbstract Pancreatic cancers are devastating diseases with five year survival rate less thanCurrentlythere is no effective treatment for advanced diseaseOne major barrier to efficacy of anti tumor therapeutics is the dense desmoplastic stromal responseEvidence suggests that cancer associated pancreatic stellate cellsCAPaSCproduce the stromal collagenThe ECM laid down by CAPaSC is considered to be o ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Deriving Bone Density from Thoracic CT Scans, STTR Phase II
SBC: BDI, Inc. Topic: NIAMSABSTRACT Osteoporosis is a major cause of disability and morbidity in our populationAs many asmillion Americans have osteoporosis andmillion more have osteopeniaHoweverbone mineral densityBMDassessment does not occur in many Americans when indicated and measure currently requires a separate referral and separate imaging scan to obtain BMDThe result is that onlyof Americans who are at risk of suffe ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
HLS- Cyclic CAR peptide: a targeted therapy for pulmonary hypertension
SBC: VASCULAR BIOSCIENCES, INC. Topic: NHLBIPUBLIC ABSTRACT This projectin response to announcement HLSdescribes a development program for CARSKNKDCCARa synthetic cyclic peptide that selectively targets diseased pulmonary vascular endothelium and enhances the therapeutic effect of vasodilator therapiesfor the treatment of pulmonary hypertensionPHPH is a disorder of elevated pulmonary vascular resistance characterized by progressive thickeni ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Development of Pirenzepine for CIPN
SBC: WinSanTor, Inc. Topic: NCIPROJECT SUMMARY Chemotherapy induced peripheral neuropathyCIPNis a debilitating condition that afflictsof cancer patients undergoing chemotherapy and limits the dose and duration of treatmentSymptoms range from sensory loss to painful neuropathy and are accompanied by electrophysiological and structural indices of nerve damageThe American Society of Clinical Oncology currently makes no recommendat ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
The nGoggle: A portable brain-based device for assessment of visual function deficits
SBC: NGOGGLE INC Topic: NPROJECT SUMMARY Assessment of loss of visual function outside the foveal area is an essential component of the management of numerous conditionsincluding glaucomaretinal and neurological disordersDespite the significant progress achieved with the development of standard automated perimetrySAPmany decades agoassessment of visual field loss with SAP still has significant drawbacksSAP testing is limi ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Detection and Staging of Liver Fibrosis by Precise MRI (pMRI)
SBC: INLIGHTA BIOSCIENCES L.L.C. Topic: NIAAAAbstract Chronic liver injury due to alcohol, metabolic dysfunction, viral hepatitis, or autoimmune disease results in liver inflammation and fibrosis. Liver fibrosis will progress to cirrhosis which is estimated to affect 1–2% of the world’s population. The major clinical consequences of cirrhosis are liver failure and hepatocellular carcinoma (HCC), both of which increase the risk of death. ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
A nanoparticle delivery system for CRISPR/Cas9 based therapeutics
SBC: ATGC Inc. Topic: 100Abstract Applications of customizable nucleases such as CRISPRclustered regularly interspaced short palindromic repeatsCasCRISPR associated proteinhave enabled efficient and precise gene correction in vitroand hold promises for eventually achieving in vivo gene correction therapyHoweverto apply CRISPR Casin therapeutic settingsseveral major challenges remain to be addressedihomologous recombinatio ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
A Method to Increase Buprenorphine Treatment Capacity and Effectiveness
SBC: CBT4CBT LLC Topic: R42The goal of this fast track STTR proposal is to expand buprenorphine maintenance therapy for opioiddependent patientsOvermillion people in the US are addicted to opiatesProviding effective agonist therapymethadone or buprenorphinecoupled with behavioral counseling greatly improves outcomesreduces morbidityand reduces societal costsMethadone maintenance treatment has been limited due to complex sta ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
OC-Go: Facilitating fidelity and dissemination of evidence based treatment for childhood OCD via an interactive crowd-sourced patient-provider tool
SBC: VIRTUALLY BETTER INC Topic: 104The long term objective of this project is to leverage mobile technologies and crowdsourcing to create a new paradigm of evidence based treatment delivery and disseminationas current methods are often insufficientThe project seeks to refine and assess OC Goa HIPAA compliant web based clinician portal and patient side mobile application designed to increase patient adherence to evidence based treat ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Testing a male oral contraceptive targeting Eppin
SBC: EPPIN PHARMA INC Topic: NICHDThe global contraceptives market was valued at $billion inand is expected to grow at a CAGR offromtoto reach an estimated value of $billion inThe contraceptive market consists of short term methods such as condoms and oral contraceptionlong term methods including implants and IUDsand permanent methods such as tubal ligations and vasectomiesEppin Pharmaandapos s product has a unique set of characte ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health